WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Results 1-10 of 2,420 for Criteria: Office(s):all Language:EN Stemming: true maximize
prev 1 2 3 4 5 6 7 8 9 10 next
Page: / 243  Go >
RSS iconmap icon 

Analysis
Analysis

List Length
Machine translation
TitleCtrPubDate
Int.ClassAppl.NoApplicantInventor
1. WO/2015/060702 PHARMACEUTICAL COMPOSITION FOR CONTROLLING BODY MASS GAIN COMPRISING S-PHENOTROPILWO30.04.2015
A61K 9/00
PCT/LV2014/000011LATVIAN INSTITUTE OF ORGANIC SYNTHESIS KALVINS, Ivars
The invention relates to medicine, in particular S-Phenotropil ((S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide) containing pharmaceutical compositions and their use in control of body mass gain.

2. WO/2015/034394 PLATINUM ALLOY FOR CATALYST GAUZESWO12.03.2015
C22C 5/04
PCT/RU2014/000588OTKRYTOYE AKTSIONERNOYE OBSHCHESTVO "KRASNOYARSKIY ZAVOD TSVETNYKH METALLOV IMENI V.N. GULIDOVA" ОТКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "КРАСНОЯРСКИЙ ЗАВОД ЦВЕТНЫХ МЕТАЛЛОВ ИМЕНИ В.Н. ГУЛИДОВА"EFIMOV, Waleriy Nikolaevich ЕФИМОВ, Валерий Николаевич
The invention relates to the field of the metallurgy of noble metals, and more particularly to platinum alloys for the manufacture of catalyst gauzes that can be used in the chemical industry. The claimed alloy contains the following components (in wt%): 15.5-16.5 palladium; 2.7-3.3 rhodium; 0.005-3.3 tantalum; the remainder platinum. The aim of the invention is to develop a composition for a platinum alloy for catalyst gauzes which provides the formation of a homogeneous fine-grained structure during the production of cast billets and semi-finished products, has stable mechanical properties and enables the long-term use of catalyst bundles manufactured from said alloy, while maintaining a high level of catalytic activity.

3. WO/2015/025164 AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTSWO26.02.2015
C07C 235/52
PCT/GB2014/052558TAKEDA PHARMACEUTICAL COMPANY LIMITED BUFFHAM, William
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein R1. X, m. R2, Y, R3, Z, n, R4. A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

4. WO/2015/025752 PLANT CULTIVATION SYSTEM AND PLANT CULTIVATION METHODWO26.02.2015
A01G 31/00
PCT/JP2014/071141MEBIOL INC. メビオール株式会社YOSHIOKA, Hiroshi 吉岡 浩
[Problem] To solve a problem that, when the bottom surface of a polyvinyl alcohol (PVA)-based film is brought into contact with a nourishing solution and a plant is cultivated on the film over a long period of time, the plant's roots penetrate through the film. [Solution] A system for plant cultivation and a plant cultivation method, characterized in that the PVA-based film has an equilibrium swelling degree in water (at 30oC) of 125-250% inclusive and a loss tangent (tan δ) in an equilibrium swelling state in water (at 30oC) of 0.005-0.2 inclusive. [Industrial applicability] The system and method according to the present invention, which enable plant cultivation over a long period of time while protecting the plant from infection with microorganisms etc. inducing plant diseases, can be used in the fields of agriculture and pharmaceutical industry.

5. WO/2015/022662 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEKWO19.02.2015
C07D 471/04
PCT/IB2014/063916NOVARTIS AG BOCK, Mark Gary
The present invention relates to compounds of formula I in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

6. WO/2015/015378 HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOFWO05.02.2015
C07D 401/14
PCT/IB2014/063383PFIZER INC. BLINN, James, Robert
The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

7. WO/2015/011730 FORMULATION COMPRISING A HYPOLIPIDEMIC AGENTWO29.01.2015
A61K 9/20
PCT/IN2014/000489CADILA HEALTHCARE LIMITED PATEL, Jitendre, D.
The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. formula (I)

8. WO/2015/004243 DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATIONWO15.01.2015
A61K 9/00
PCT/EP2014/064824CHIESI FARMACEUTICI S.P.A. MUSA, Rossella
The invention relates to dry powder formulations for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid, their process of preparation and therapeutic uses thereof.

9. WO/2015/006033 PROVIDING A PHARMACOKINETIC DRUG DOSING REGIMEWO15.01.2015
B23P 17/04
PCT/US2014/043517BAXALTA INCORPORATED LOEW-BASELLI, Alexandra
A system and method for providing a therapeutic plasma protein dosing regime includes determining a pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The example system and method also include determining a first dosing regime for a first specified dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient over a time period based at least upon the pharmacokinetic profile and determining a second dosing regime for a second specified dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient over the time period based at least upon the pharmacokinetic profile. The example system and method further include displaying the first dosing regime and the second dosing regime on a client device such that the first dosing regime is displayed in conjunction with the second dosing regime.

10. WO/2015/001573 SYNERGISTIC COMPOSITIONSWO08.01.2015
A61K 31/40
PCT/IN2014/000445CADILA HEALTHCARE LIMITED JAIN, Mukul, R.
The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (la) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of : these novel salts and use thereof.


Results 1-10 of 2,420 for Criteria: Office(s):all Language:EN Stemming: true
prev 1 2 3 4 5 6 7 8 9 10 next